A new poll reveals enthusiasm for a pricey new generation of weight loss drugs, but interest drops if users potentially have to deal with weekly injections, lack of insurance coverage, or a need to continue the medications indefinitely to avoid regaining weight.

Related Keywords

Massachusetts , United States , Americans , Fatima Cody Stanford , Ashley Kirzinger , Eli Lilly , Harvard Medical School , Morgan Stanley , Novo Nordisk , Many Americans , California Healthline , Massachusetts General Hospital , Harvard Medical ,